IFM Investors Pty Ltd raised its position in shares of Becton Dickinson and Co (NYSE:BDX) by 11.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,188 shares of the medical instruments supplier’s stock after purchasing an additional 1,768 shares during the quarter. IFM Investors Pty Ltd’s holdings in Becton Dickinson and were worth $4,292,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in BDX. Oregon Public Employees Retirement Fund grew its stake in shares of Becton Dickinson and by 22,485.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 6,545,502 shares during the period. Ronna Sue Cohen grew its stake in shares of Becton Dickinson and by 24,129.0% during the 1st quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock valued at $5,734,000 after purchasing an additional 5,710,365 shares during the period. Norges Bank bought a new stake in shares of Becton Dickinson and during the 4th quarter valued at about $515,703,000. Morgan Stanley grew its stake in shares of Becton Dickinson and by 133.0% during the 3rd quarter. Morgan Stanley now owns 2,771,269 shares of the medical instruments supplier’s stock valued at $723,303,000 after purchasing an additional 1,581,829 shares during the period. Finally, Mackenzie Financial Corp grew its stake in shares of Becton Dickinson and by 27.7% during the 4th quarter. Mackenzie Financial Corp now owns 1,943,752 shares of the medical instruments supplier’s stock valued at $437,966,000 after purchasing an additional 421,825 shares during the period. Institutional investors and hedge funds own 84.87% of the company’s stock.

Shares of NYSE:BDX opened at $227.89 on Friday. The company has a market cap of $61.32 billion, a P/E ratio of 20.70, a P/E/G ratio of 1.74 and a beta of 1.21. The company has a quick ratio of 0.62, a current ratio of 0.97 and a debt-to-equity ratio of 0.83. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.58 by $0.12. The company had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The firm’s revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.48 EPS. On average, sell-side analysts expect that Becton Dickinson and Co will post 12.08 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 8th were issued a $0.77 dividend. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.08 dividend on an annualized basis and a yield of 1.35%. Becton Dickinson and’s dividend payout ratio is presently 27.97%.

In related news, CEO Vincent A. Forlenza sold 8,309 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $255.13, for a total value of $2,119,875.17. Following the transaction, the chief executive officer now directly owns 222,785 shares of the company’s stock, valued at approximately $56,839,137.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Ribo Alberto Mas sold 2,104 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $255.00, for a total value of $536,520.00. Following the completion of the transaction, the executive vice president now directly owns 19,074 shares in the company, valued at $4,863,870. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,684 shares of company stock worth $7,518,574. 0.12% of the stock is owned by insiders.

BDX has been the subject of a number of recent research reports. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. Raymond James cut their price objective on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a research note on Tuesday, March 19th. Citigroup cut their price objective on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating for the company in a research note on Wednesday, January 2nd. Piper Jaffray Companies boosted their price objective on Becton Dickinson and to $274.00 and gave the company an “overweight” rating in a research note on Tuesday, February 5th. Finally, Morgan Stanley cut their price objective on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Becton Dickinson and currently has a consensus rating of “Buy” and an average target price of $256.25.

TRADEMARK VIOLATION NOTICE: “IFM Investors Pty Ltd Purchases 1,768 Shares of Becton Dickinson and Co (BDX)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2019/04/20/ifm-investors-pty-ltd-purchases-1768-shares-of-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Channel Trading

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.